Peptide R&D could be a major tailwind for Nautilus Biotechnology because developers need proteoform data to understand treatment effects. Demand could rise next year if peptide success drives R&D, depending on its rollout and assays. AI-driven biology also needs measurements to validate models regardless of which therapies win. Personalized peptide care is years or a decade away, requiring clinical validation, approval and much cheaper profiling; Nautilus must still prove scale and economics. … Show more

Nautilus Biotechnology is entering commercialization and could become the Illumina of proteomics. Its early access program signed Baylor College of Medicine as first customer for an NIH-funded cancer project. Its tau assay with the Buck Institute quantifies up to 768 full-length tau proteoforms, beyond traditional methods, which could draw pharma demand or M&A interest as Alzheimer's drug work heats up. Its $143 million cash lasts past 2028 at $14-16 million quarterly burn, avoiding dilution. … Show more

Nautilus Biotechnology is wildly overvalued at about $250M on just $190K of trailing-12-month revenue, a price richer than early-stage VC. That rebuts @alc2022's case that it owns the read layer for the proteome and could return 100-1,000x. x.com 

Biotech's usual Q4 strength ahead of JPM season makes aggressive rallies in smaller names highly likely. ARKG is starting to break out, and PDS Biotechnology is showing multiple buy signals. If ARKG keeps running as expected, Nautilus Biotechnology, PDS Biotechnology and Quantum-Si could reasonably rally toward about $10 soon; broken chart structures would invalidate that view. x.com  x.com 

Voyager's single-molecule approach could make Nautilus the most asymmetric proteomics bet if it works. Quarterly grant revenue of about $0.2m against over $10m consumed leaves it reliant on capital; a $125m ATM risks dilution. Repeated slips make the mid-2027 launch less likely to hold; independent customer validation and a sales channel are absent. Adoption could justify billions; delay or low-price issuance could send shares below $2 again. Tempus AI remains the preferred larger holding. x.com 

Nautilus Biotechnology remains too speculative and faces eventual Nasdaq delisting if it cannot hold above $1. A price floor just under $1 after its collapse looks technically supportive, and there are early signs of commercial interest, but it is still a wild card. x.com 

Zeta Global and Nautilus Biotechnology are two versions of the same idea, seeing deeper than anyone else: Zeta into the customer, Nautilus into the molecule. Both are aligned with something everyone wants, better information, and moved first to build the platforms that deliver it. Neither guarantees success, but both greatly raise the odds, which creates the asymmetry. Zeta is much further along in its zero-to-one journey. x.com 

AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more

Tempus AI's new pharma contracts put cash payments behind its data and AI platform, beyond diagnostics. Bristol Myers Squibb renewed and expanded oncology-data and Lens access for $137.5M in fixed payments through 2031; Pathos agreed to pay up to $55M for 500,000 neurology records and updates over five years, depending on delivery. Together the deals total up to $192.5M, meaningful validation though not an enormous sum. x.com 

Hims & Hers, Nautilus Biotechnology, Viking Therapeutics, Protagonist Therapeutics and Eli Lilly have 10x potential as peptide-related stocks; peptides will create generational wealth this year. Nautilus has a $230 million market cap, Viking $3.5 billion, Protagonist $9.1 billion and Lilly $1.1 trillion. x.com  x.com  x.com  x.com  x.com